ACB
HAE icon

Aristotle Capital Boston’s Haemonetics HAE Stock Holding History

Aristotle Capital Boston’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.5M Sell
346,386
-23,922
-6% -$1.56M 1.21% 25
2025
Q4 		$29.7M Sell
370,308
-33,854
-8% -$2.27M 1.63% 11
2025
Q3 		$19.7M Buy
404,162
+41,215
+11% +$2.55M 1.02% 35
2025
Q2 		$27.1M Sell
362,947
-28,914
-7% -$1.91M 1.38% 22
2025
Q1 		$24.9M Buy
391,861
+11,244
+3% +$765K 1.24% 25
2024
Q4 		$29.7M Buy
380,617
+22,011
+6% +$1.77M 1.1% 33
2024
Q3 		$28.8M Buy
358,606
+55,232
+18% +$4.46M 0.95% 45
2024
Q2 		$25.1M Sell
303,374
-18,152
-6% -$1.6M 0.84% 50
2024
Q1 		$27.4M Buy
321,526
+16,246
+5% +$1.27M 0.83% 49
2023
Q4 		$26.1M Sell
305,280
-6,386
-2% -$552K 0.8% 53
2023
Q3 		$27.9M Sell
311,666
-1,330
-0.4% -$119K 0.9% 46
2023
Q2 		$26.6M Buy
312,996
+7,212
+2% +$610K 0.8% 48
2023
Q1 		$25.3M Buy
305,784
+7,634
+3% +$618K 0.78% 52
2022
Q4 		$23.4M Sell
298,150
-7,721
-3% -$621K 0.74% 58
2022
Q3 		$22.6M Sell
305,871
-26,140
-8% -$1.88M 0.77% 51
2022
Q2 		$21.6M Buy
332,011
+21,396
+7% +$1.27M 0.65% 65
2022
Q1 		$19.6M Sell
310,615
-6,697
-2% -$364K 0.5% 88
2021
Q4 		$16.8M Sell
317,312
-5,688
-2% -$347K 0.39% 104
2021
Q3 		$22.8M Buy
323,000
+73,322
+29% +$4.63M 0.53% 84
2021
Q2 		$16.6M Sell
249,678
-14,050
-5% -$994K 0.38% 100
2021
Q1 		$29.3M Buy
263,728
+32,258
+14% +$3.99M 0.65% 70
2020
Q4 		$27.5M Sell
231,470
-12,839
-5% -$1.38M 0.65% 65
2020
Q3 		$21.3M Buy
+244,309
New +$21.4M 0.62% 66

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aristotle Capital Boston's HAE Position: Q1 2026 in Review

Aristotle Capital Boston reduced its Haemonetics (HAE) stake by 6.5% in Q1 2026, selling an estimated $1.56M and leaving 346,386 shares worth $19.5M. The position accounts for 1.21% of the portfolio, ranked #25.

Aristotle Capital Boston first reported a position in HAE in Q3 2020 and has held it in 23 quarters since. The position peaked at $29.7M in Q4 2024. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Aristotle Capital Boston held 346,386 shares of Haemonetics worth $19.5M as of Q1 2026.
  • Aristotle Capital Boston sold 23,922 Haemonetics shares in Q1 2026, an estimated $1.56M.
  • Haemonetics made up 1.21% of Aristotle Capital Boston's portfolio in Q1 2026, its #25 holding.
  • Aristotle Capital Boston first reported a position in Haemonetics in Q3 2020 and has held it in 23 quarters since.
  • Aristotle Capital Boston's Haemonetics position peaked at $29.7M in Q4 2024.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Aristotle Capital Boston's 13F filing for Q1 2026, filed 15 May 2026.